On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key ...
Number 4: The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis ...
Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab biosimilar candidate (Stoboclo and Osenvelt) and its aflibercept biosimilar ...
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis' ...
Travis Brewer, vice president of payer and public health strategy at Texas Oncology, discusses the role of biosimilars in making cancer care more affordable and accessible, as well as the need for ...
Sarfaraz K. Niazi, PhD, gives his opinion on how the recent IQVIA report “Assessing the Biosimilar Void in the US” could be ...
Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback